Communication
Wiley-VCH, Weinheim, 2001, pp. 187–220; c) as of April 2016, 12 drugs
containing pyrrole rings (fused heteroarenes such as indoles and conju-
gated porphyrins not included) have been approved: https:
a) V. Estévez, M. Villacampa, J. C. Menéndez, Chem. Soc. Rev. 2010, 39,
4402–4421; b) N. Bailey, E. Demont, N. Garton, H.-X. Seow, Synlett 2008,
2, 185–188.
614; d) M. Mahlau, B. List, Angew. Chem. Int. Ed. 2013, 52, 518–533;
Angew. Chem. 2013, 125, 540–556; e) K. Brak, E. N. Jacobsen, Angew.
Chem. Int. Ed. 2013, 52, 534–561; Angew. Chem. 2013, 125, 558–588; f)
S. Shirakawa, K. Maruoka, Angew. Chem. Int. Ed. 2013, 52, 4312–4348;
Angew. Chem. 2013, 125, 4408–4445.
[4]
[5]
[17] C. Hubert, J. Moreau, J. Batany, A. Duboc, J.-P. Hurvois, J.-L. Renaud, Adv.
Synth. Catal. 2008, 350, 40–42.
[18] a) T. Honjo, R. J. Phipps, V. Rauniyar, F. D. Toste, Angew. Chem. Int. Ed.
2012, 51, 9684–9688; Angew. Chem. 2012, 124, 9822–9826; b) similar
results were obtained for (R)-4-Ph-PhDAP (data not shown), see: K. Hira-
matsu, T. Honjo, V. Rauniyar, F. D. Toste, ACS Catal. 2016, 6, 151–154.
[19] See Table S1 in the Supporting Information for details.
[20] For some substrates reactions using Selectfluor and Na3PO4 in THF with-
out a catalyst afforded similar or slightly decreased yields relative to the
reactions using Selectfluor, Na3PO4, and a catalyst in THF.
a) M. E. Crestoni, J. Labelled Compd. Radiopharm. 1990, 28, 1109–1112;
b) M. E. Crestoni, S. Fornarini, Gazz. Chim. Ital. 1989, 119, 203–204; c) G.
Cerichelli, M. E. Crestoni, S. Fornarini, Gazz. Chim. Ital. 1990, 120, 749–
755.
a) K. D. Barnes, D. A. Hunt, Synth. Commun. 1994, 24, 1749–1755; b) E.
Dvornikova, M. Bechcicka, K. Kamieńska-Trela, A. Krówczyński, J. Fluorine
Chem. 2003, 124, 159–168; c) T. Higashino, A. Osuka, Chem. Asian J.
2013, 8, 1994–2002.
S. Yamada, A. Gavryushin, P. Knochel, Angew. Chem. Int. Ed. 2010, 49,
2215–2218; Angew. Chem. 2010, 122, 2261–2264.
Y. Zhang, K. Shibatomi, H. Yamamoto, Synlett 2005, 18, 2837–2842.
a) J. Wang, A. I. Scott, Tetrahedron Lett. 1994, 35, 3679–3682; b) J. Wang,
A. I. Scott, Tetrahedron 1994, 50, 6181–6192.
[6]
[21] D. Landini, A. Maia, F. Montanari, F. M. Pirisi, J. Chem. Soc. Perkin Trans. 2
1980, 46–51.
[7]
[22] Treating 15 with 3 equiv. of Selectfluor, 2 equiv. of Na3PO4, and 0.5 equiv.
of (R)-PhDAP in THF afforded 15a and 15b in 32 and 12 % yield, respec-
tively, while the starting material was recovered in 5 % yield.
[23] 1,5,6,7-Tetrahydro-4H-indol-4-one (4), methyl 2-ethyl-1H-pyrrole-3-carb-
oxylate (6), and ethyl 2-methyl-4-phenyl-1H-pyrrole-3-carboxylate (7):
[8]
[9]
[10] H. Onda, H. Toi, Y. Aoyama, H. Ogoshi, Tetrahedron Lett. 1985, 26, 4221–
4224.
[11] T. Tajima, H. Ishii, T. Fuchigami, Electrochem. Commun. 2001, 3, 467–471.
[12] a) M. Campbell, T. Ritter, Chem. Rev. 2015, 115, 612–633; b) P. J. Milner,
Y. Ynag, S. L. Buchwald, Organometallics 2015, 34, 4775–4780.
[13] a) R. E. Banks, S. N. Mohialdin-Khaffaf, G. S. Lal, I. Sharif, R. G. Syvret, J.
Chem. Soc., Chem. Commun. 1992, 595–596; b) P. T. Nyffeler, S. G. Durón,
M. D. Burkart, S. P. Vincent, C.-H. Wong, Angew. Chem. Int. Ed. 2005, 44,
192–212; Angew. Chem. 2005, 117, 196–217.
[14] J. Wang, A. I. Scott, J. Chem. Soc., Chem. Commun. 1995, 2399–2400.
[15] B. Troegel, T. Lindel, Org. Lett. 2012, 14, 468–471.
[16] a) V. Rauniyar, A. D. Lackner, G. L. Hamilton, F. D. Toste, Science 2011,
334, 1681–1684; b) R. J. Phipps, K. Hiramatsu, F. D. Toste, J. Am. Chem.
Soc. 2012, 134, 8376–8379; for recent reviews on phase-transfer catalysis,
see: c) R. J. Phipps, G. L. Hamilton, F. D. Toste, Nat. Chem. 2012, 4, 603–
[24] DFT calculations suggest that these two positions show negative electro-
static properties.
[25] W. G. Frederick, G. K. Jason, K. Thierry, W. D. P. Matthew, P. T. Nick, Drug
Discovery Today 2015, 20, 11–17.
Received: May 10, 2016
Published Online: ■
Eur. J. Org. Chem. 0000, 0–0
4
© 0000 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim